The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis

Guihard, Soizic; Clay, Denis; Cocault, L; Saulnier, N.; Opolon, Paule; Souyri, Michèle; Pagès, Gilles; Pouysségur, Jacques; Porteu, Françoise; Gaudry, Muriel

doi:10.1182/blood-2009-09-242487

Cited by 45 publications

(54 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Similarly, our analysis of 10 previous studies using CD71 in conjunction with forward scatter also reveals large inconsistencies in the ratio of Pro:Baso:Poly:Ortho in normal murine bone marrow. 6,[20][21][22][23][24][25][26][27][28] None of these studies were able to document physiologic progression of terminal erythroid differentiation in normal bone marrow. As such, the reported stage-specific erythropoietic defects in various genetically engineered mice using CD71 as a marker is highly problematic.…”

Section: Discussionmentioning

confidence: 99%

Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis

Liu

Zhang

Ginzburg

et al. 2013

Blood

202

214

View full text Add to dashboard Cite

Key Points• The study establishes a reliable method to quantify differentiating mouse erythroblasts and to monitor terminal mouse erythropoiesis in vivo.• Quantitative analysis of erythropoiesis of thalassemia mice revealed stage-specific changes in terminal erythroid differentiation.Terminal erythroid differentiation is the process during which proerythroblasts differentiate to produce enucleated reticulocytes. Although it is well established that during murine erythropoiesis in vivo, 1 proerythroblast undergoes 3 mitosis to generate sequentially 2 basophilic, 4 polychromatic, and 8 orthochromatic erythroblasts, currently there is no method to quantitatively monitor this highly regulated process. Here we outline a method that distinguishes each distinct stage of erythroid differentiation in cells from mouse bone marrow and spleen based on expression levels of TER119, CD44, and cell size. Quantitative analysis revealed that the ratio of proerythroblasts:basophilic: polychromatic:orthromatic erythroblasts follows the expected 1:2:4:8 ratio, reflecting the physiologic progression of terminal erythroid differentiation in normal mice. Moreover, in 2 stress erythropoiesis mouse models, phlebotomy-induced acute anemia and chronic hemolytic anemia because of 4.1R deficiency, the ratio of these erythroblast populations remains the same as that of wild-type bone marrow. In contrast, in anemic ␤-thalassemia intermedia mice, there is altered progression which is restored to normal by transferrin treatment which was previously shown to ameliorate the anemic phenotype. The means to quantitate in vivo murine erythropoiesis using our approach will probably have broad application in the study of altered erythropoiesis in various red cell disorders. (Blood. 2013;121(8):e43-e49)

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis

Liu

Zhang

Ginzburg

et al. 2013

Blood

202

214

View full text Add to dashboard Cite

show abstract

“…Additionally, there were excessive numbers of erythroid progenitors in the spleen with enhanced survival ability mediated by decreased Fas and FasL levels. Expression and activation of ERK2 was normal suggesting that ERK1 plays a unique role in erythropoiesis [97].…”

Section: Differential Signaling Requirementsmentioning

confidence: 98%

Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development

Chung

Kondo

2010

Immunol Res

View full text Add to dashboard Cite

Recent research on hematological malignancies has shown that malignant cells often co-opt physiological pathways to promote their growth and development. Bone marrow homeostasis requires a fine balance between cellular differentiation and self-renewal; cell survival and apoptosis; and cellular proliferation and senescence. The Ras/Raf/MEK/ERK pathway has been shown to be important in regulating these biological functions. Moreover, the Ras/Raf/MEK/ERK pathway has been estimated to be mutated in 30% of all cancers, thus making it the focus of many scientific studies which have lead to a deeper understanding of cancer development and help to elucidate potential weaknesses that can be targeted by pharmacological agents [1]. In this review, we specifically focus on the role of this pathway in physiological hematopoiesis and how augmentation of the pathway may lead to hematopoietic malignancies. We also discuss the challenges and success of targeting this pathway.

show abstract

“…57 For ERKs, Erk1 2/2 mice exhibit heightened splenic erythropoiesis and hematocrits. 62 RAS-like GTPases can also regulate EPO-dependent EPC formation. As a new EPO/EPOR target gene and Roco family GTPase, malignant fibrous histiocytoma-amplified sequences with leucinerich tandem repeats 1 (MASL1) supports C-RAF/MEK/ERK activation and primary human erythroblast development.…”

Section: Epor Signal Transduction Via Rat Sarcoma/ Mek Kinase/mitogenmentioning

confidence: 99%

Emerging EPO and EPO receptor regulators and signal transducers

Kuhrt

Wojchowski

2015

Blood

146

129

View full text Add to dashboard Cite

As essential mediators of red cell production, erythropoietin (EPO) and its cell surface receptor (EPO receptor [EPOR]) have been intensely studied. Early investigations defined basic mechanisms for hypoxia-inducible factor induction of EPO expression, and within erythroid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5), rat sarcoma/mitogen-activated protein kinase/ extracellular signal-regulated kinase (RAS/ MEK/ERK), and phosphatidylinositol 3-kinase (PI3K) pathways. Contemporary genetic, bioinformatic, and proteomic approaches continue to uncover new clinically relevant modulators of EPO and EPOR expression, and EPO's biological effects. This Spotlight review highlights such factors and their emerging roles during erythropoiesis and anemia. (Blood. 2015;125(23):3536-3541)

show abstract

The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis

Cited by 45 publications

References 43 publications

Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis

Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis

Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development

Emerging EPO and EPO receptor regulators and signal transducers

Contact Info

Product

Resources

About